1. Chemical identity reference
Public chemical databases list Palmitoylethanolamide under the stated identity; this reference supports identity review and does not replace the batch COA.
Citation: PubChem compound recordView source
Sample Available
PEA
CAS 544-31-0
Palmitoylethanolamide Powder
Purity≥99.0% (HPLC)
Palmitoylethanolamide powder for capsule and tablet development with particle-size evaluation
Palmitoylethanolamide Powder (CAS 544-31-0), specification ≥99.0% (HPLC). Palmitoylethanolamide, abbreviated PEA; particle size and dispersion are evaluated separately for ordinary powder and any specified micronized grade. Batch COA and evaluation samples are available. MOQ: 1 kg. nutrition & functional ingredients
Quote / sample & deliveryMW299.5 g/mol
Key Specifications
| Product Positioning | Palmitoylethanolamide powder for capsule and tablet development with particle-size evaluation |
| Application Scenarios | lipid formulation screening · professional research supply · solid-dose development |
| CAS Number | 544-31-0 |
| Purity | ≥99.0% (HPLC) |
| Molecular Formula | C18H37NO2 |
| Molecular Weight | 299.5 g/mol |
| Appearance | White to off-white crystalline powder |
| Solubility | Practically insoluble in water; confirm dispersion system |
| Storage | Sealed, cool, dry and protected from light |
| Shelf Life | 2 years |
Procurement & delivery
Supply details confirmed by intended use, volume and target market
Purity ≥99.0% (HPLC)CAS 544-31-0
MOQ1 kg
Lead Time3–5 business days, subject to qualification
Packaging1 g / 100 g / 1 kg / 25 kg
Free sample available
View quality documents ↓What Is PEA?
Palmitoylethanolamide (PEA), also known as palmidrol (CAS 544-31-0) is supplied as a white to off-white crystalline powder for formulation and research projects. PathGene offers bulk raw material with a ≥99.0% HPLC purity specification, batch documentation and evaluation samples. For capsule, tablet or powder-blend projects, include the required particle-size distribution or mesh specification in your inquiry. Our supply discussion covers the material specification, sample evaluation, packaging and delivery schedule.
Other Names
PEAPalmitoyl ethanolamidePalmitic acid monoethanolamideCAS 544-31-0Palmidrol
Key Features
🔬
≥99.0% HPLC Purity
High-purity PEA raw material with batch-specific quality documentation. Batch PGPEA-260304 recorded HPLC purity of 99.83%.
🧪
Ingredient Identity
Palmitoylethanolamide, abbreviated PEA; particle size and dispersion are evaluated separately for ordinary powder and any specified micronized grade.
🔬
Batch COA
Review the batch purity, loss on drying and reported residual-solvent results through the quality-documents section.
📦
Evaluation Samples
Request a sample for incoming quality checks and formulation trials. Share the sample quantity, dosage form and priority tests.
📋
Bulk Supply and Packaging
MOQ: 1 kg. Send quantity, package sizes and destination to discuss bulk pricing and delivery.
Recent batch test data
Test items, specifications and results for the listed batch are shown here. View or request a COA in the quality documents section.
Batch No.
PGPEA-260304
Test date
2026-03-07
Specification
Q/PG-INHOUSE
Pack size
25 kg/barrel
Storage
Sealed, cool, dry and protected from light
Conclusion
Conforms
| Test Item | Specification | Result |
|---|---|---|
| Appearance | White to off-white crystalline powder | Complies |
| Purity (HPLC) | ≥99.0% | 99.83% |
| Loss on drying | ≤1.0% | 0.02% |
| Methanol | ≤0.3% | Not detected |
| Ethanol | ≤0.5% | Not detected |
| Ethyl acetate | ≤0.5% | Not detected |
View an available COA in the quality documents section. Check the document for its product form and batch; request a signed COA for your purchasing or shipment batch separately.
Applicable Dosage Forms
Hard capsules
Powders
Softgels
Tablets
Sublingual tablets
Oral dissolving films
Palmitoylethanolamide development essentials
Assess PEA particle size/micronization separately from chemical purity; verify the combination and particle form used in each study.
99.83%
Purity (HPLC)
PGPEA-260304 · Results apply to this lot; interpret purity, assay and water on their respective bases.
- Composition candidates:
- Screen dispersion carriers and flow aids for capsules; premix PEA and polydatin separately without equating simple blending with co-micronized formulations.
- Processing priorities:
- Compare particle-size distribution, agglomeration and mixing time; check identity, assay and dissolution/dispersion before and after processing.
- Testing priorities:
- PEA assay, particle size, uniformity, disintegration/dispersion, impurities and packaged stability.
Palmitoylethanolamide formulation development: composition, processing and validation
Composition candidates, processing sequences and tests support pilot design. Confirm candidate excipients and processes using this material in the actual finished formulation.
Solid formats: carriers, loading and mixing
- Define loading by ingredient mass, salt mass or active moiety. Use m = target mass / assay as supplied only when both share the same basis; convert dried-basis assays using water where appropriate, and do not substitute HPLC area purity for mass assay. Set excipient amounts from fill mass, bulk density and uniformity trials.
- Screen dispersion carriers and flow aids for capsules; premix PEA and polydatin separately without equating simple blending with co-micronized formulations.
- Record ingredient lots, actual component masses, loading bases and addition sequence, retaining blanks and single-ingredient controls for traceable changes.
Processing and formats: pilot batches through filling
- Compare particle-size distribution, agglomeration and mixing time; check identity, assay and dissolution/dispersion before and after processing.
- Select blending/filling equipment for the actual format, recording size, bulk density, mixing time and fill mass; liquid or softgel routes need separate carrier, sedimentation and container/shell compatibility testing.
Validation and scale-up: tests, retained samples and packaging
- PEA assay, particle size, uniformity, disintegration/dispersion, impurities and packaged stability.
- Sample upper/middle/lower positions and start/middle/end filling; compare with ingredients, process blanks and single-ingredient results, documenting deviations and corrections.
- Include actual packaging, transport and intended storage in retained-sample plans; ingredient COAs and storage conditions do not establish a new finished-product shelf life.
Research combinations and formulation directions
Study combinations, individual-ingredient mechanisms and product precedents are distinguished; expand each entry for scope and pilot-development checks.
Human combination studyPEA + polydatin: specific combination research
The human study evaluated a specific PEA/polydatin combination. Its abstract alone does not establish co-micronization; verify simple blending, micronization and co-micronization separately. A clinical formulation does not validate this ingredient.
Expand research and formulation notes +Collapse research and formulation notes −
Development rationale: The human study evaluated a specific PEA/polydatin combination. Its abstract alone does not establish co-micronization; verify simple blending, micronization and co-micronization separately. A clinical formulation does not validate this ingredient.
Evidence scope: The human study evaluated a specific PEA/polydatin combination. Its abstract alone does not establish co-micronization; verify simple blending, micronization and co-micronization separately. A clinical formulation does not validate this ingredient.
Pilot checks: Retain individual-ingredient, blend and carrier controls; check uniformity and post-process assays before packaged samples, documenting study formulations separately from new candidates.
2017 · Randomised clinical trial: the analgesic properties of dietary supplementation with palmitoylethanolamide and polydatin in irritable bowel syndrome. ↗Literature-Supported Research Directions
Scientific Research
2. Human experimental-pain research
A randomized, double-blind crossover study in 14 healthy volunteers evaluated four weeks of PEA using an experimental heat-pain model and measures of central and peripheral sensitization. It was a small mechanistic study in healthy people, not evidence that this raw material treats a clinical condition.
Citation: Lang-Illievich et al. The Effect of Palmitoylethanolamide on Pain Intensity, Central and Peripheral Sensitization, and Pain Modulation in Healthy Volunteers-A Randomized, Double-Blinded, Placebo-Controlled Crossover Trial. Nutrients (2022). PMID: 36235736.View source
3. Clinical-trial evidence varies by formulation
A 2025 systematic review identified 47 randomized-trial reports across several populations and outcomes. The reviewed studies used differing formulations, including micronized or ultramicronized PEA, and the authors describe evidence across heterogeneous conditions. These findings should not be transferred automatically to an untested grade or particle-size specification.
Citation: Bortoletto et al. Brain, Behavior, & Immunity – Health. 2025;43:100927.View source
Note: For ingredient R&D and scientific information; findings depend on model, dose, formulation and population and do not constitute a treatment claim or efficacy guarantee.
Lead Time
3–5business days
Standard products are generally in stock; confirm the exact lead time with us.
Minimum Order
1 kg
Samples, pilot trials, and commercial volumes are supported.
Foil Pouch
Sealed, moisture-protective inner packaging
Fiber Drum
Standard outer packaging for bulk transport
Bulk Shipping
Palletized and stretch-wrapped for protection
Ambient storage: foil pouch + fiber drum; temperature controlled: foil pouch + insulated box/carton. Confirm by product.
Custom packaging: Custom foil bags or HDPE drums, GMP label printing, and export documentation are available. Contact us for a quote.Images are packaging illustrations.
Certifications
Purity & Assay Method
The stated purity and batch result are shown separately. Confirm the method, dry-basis calculation and salt or hydrate form against the current COA.
Solubility & Formulation
Formulation work should confirm concentration, pH, light, moisture and hold-time controls for Palmitoylethanolamide; suitability depends on the final format and market requirements.
What is the purity specification for PEA powder?+
Palmitoylethanolamide (PEA) powder, CAS 544-31-0, has an HPLC purity specification of ≥99.0%. Lot PGPEA-260304 reports 99.83%; that result applies to that lot. Accept the offered material against its own batch COA.
How do I specify micronized PEA requirements?+
Include the required D10, D50, D90 or mesh specification, units and measurement method. These details help align the requested grade and sample-evaluation criteria.
Can I request a PEA sample?+
Yes. Share the required sample quantity, application and destination to arrange evaluation.
What is the MOQ for PEA powder, and how do particle-size requirements affect sourcing?+
PEA powder has a 1 kg MOQ. Micronized projects additionally require agreed D10, D50, D90 or mesh values and a measurement method, with sample evaluation in the intended format. A purity of ≥99.0% alone does not specify the particle-size grade.
Why Choose PathGene
- Direct China manufacturer supply — factory pricing, no middleman
- Recent-batch COA & batch traceability
- In-house R&D + synthetic biology / enzymatic production platform
- Free sample for qualified B2B buyers before commercial order
- Flexible MOQ — from lab-scale trial to ton-scale commercial supply
- One-stop OEM/private-label support for finished dosage forms
- Worldwide shipping by courier, air freight, and sea freight
OEM & Private-Label Services
- ·Custom capsule manufacturing
- ·Custom tablet manufacturing
- ·Powder blending & custom formulation
- ·Private-label bottles, pouches & labels
- ·Small trial orders
- ·Bulk commercial production
- ·Export documentation
- ·Third-party testing support available on request
Documents Available
- ·Product specification sheet — request from sales
- ·Recent-batch COA — confirm by product and batch
- ·Other quality documents — confirm by product and batch
Documents are subject to product and batch availability; third-party reports are provided only when applicable.
Quality documents
Review specifications first, then batch data at shipment
The specification sheet defines acceptance limits. The COA shows actual batch results, which may vary by batch. Third-party reports are provided only for products or batches that have been independently tested.
Product specification
Stable acceptance criteria · Available on request
Recent-batch COA
Actual test data · Check the COA for the applicable batch
Related Products
USPEPSampleSpec sheetRecent COAThird-party report
Citicoline (CDP-Choline)
Citicoline (CDP-Choline) Powder
CAS987-78-0
Purity≥99.8%
FormulaC₁₄H₂₆N₄O₁₁P₂
USPSampleSpec sheetRecent COA
GSH
Glutathione (Reduced) Powder
CAS70-18-8
Purity≥98.0%
FormulaC₁₀H₁₇N₃O₆S
Interested in PEA?
Our R&D team will respond to your inquiry or sample request within 24 hours.
Scan to add WeChat
Alex Huang · Mon–Fri 9am–6pm CST